Cancer Research Meeting Calendar Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, J.
Right arrow Articles by Gallo, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, J.
Right arrow Articles by Gallo, J. M.
[Cancer Research 61, 5491-5498, July 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-4701

Jianguo Ma, Sharon Pulfer, Shaolan Li, Jianxiong Chu, Karin Reed and James M. Gallo2

Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

The angiogenic phenotype is associated with increased tumor neovascularization and a state of vascular hyperpermeability to macromolecules. Angiogenesis inhibitors could reverse these processes, resulting in tumor capillaries that have normal membrane permeability. It was proposed that the switch from a hyperpermeable to a normal permeable state could have the untoward effect of decreasing tumor concentrations of anticancer drugs coadministered with angiogenesis inhibitors. The current investigation evaluated a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fumagillol (TNP-470) and the alkylating agent temozolomide (TMZ), in xenograft models that differentially expressed vascular endothelial growth factor (VEGF), a driving force for angiogenesis. Nude rats bearing either s.c. low VEGF (V-) or high VEGF (V+) or intracerebral V+ gliomas were administered either a multiple-dose regimen of TNP-470 or vehicle control. One day after the last dose of vehicle or TNP-470, a steady-state dosing regimen of TMZ was administered with subsequent collection and high-performance liquid chromatography analysis of plasma and either tumor homogenate or tumor microdialysis steady-state TMZ concentrations, and in some cases [5-(3-methyltriazen-1-yl)imidazole-4-carboximide] MTIC, its active metabolite. Microvessel density (MVD) was quantitated by image analysis using an anti-CD31 method. Statistical analyses of pharmacokinetic and pharmacodynamic end points in the control and TNP-470 treatment groups were completed by nonparametric tests. In both the s.c. and intracerebral V+ models, TNP-470 treatment produced significant reductions in TMZ tumor concentrations and tumor:plasma concentration ratios compared with control, being reduced an average of 25% and 50% in the s.c. and intracerebral tumors, respectively. MTIC concentrations in V+ s.c. tumors also were reduced by 50% in the presence of TNP-470. Consistent with the lower extent of neovascularization in the V- tumors, TMZ and MTIC tumor concentrations were not different in TNP-470 and control treatment groups in s.c. tumors. MVD was reduced by TNP-470 compared with vehicle control in the V+ tumors, but was unaltered in V- tumors, attesting to the use of MVD as a pharmacodynamic end point and the effectiveness of TNP-470 as an angiogenesis inhibitor. Angiogenesis inhibitor’s pharmacodynamic actions on tumor angiogenesis can produce a reduction in tumor concentrations of coadministered anticancer agents. It is increasingly important to understand the pharmacokinetic and pharmacodynamic behavior of each class of drug so that optimal dosing regimens can be designed.




This article has been cited by other articles:


Home page
 Neuro Oncol DukeHome page
Q. Zhou and J. M. Gallo
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Neuro-oncol, January 1, 2009; 11(3): 301 - 310.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Picchio, R. Beck, R. Haubner, S. Seidl, H.-J. Machulla, T. D. Johnson, H.-J. Wester, G. Reischl, M. Schwaiger, and M. Piert
Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography
J. Nucl. Med., April 1, 2008; 49(4): 597 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Zhou, P. Guo, and J. M. Gallo
Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide
Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ma and D. J. Waxman
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Claes, P. Wesseling, J. Jeuken, C. Maass, A. Heerschap, and W. P.J. Leenders
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Mol. Cancer Ther., January 1, 2008; 7(1): 71 - 78.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M.-E. Jockovich, F. Suarez, A. Alegret, Y. Pina, B. Hayden, C. Cebulla, W. Feuer, and T. G. Murray
Mechanism of Retinoblastoma Tumor Cell Death after Focal Chemotherapy, Radiation, and Vascular Targeting Therapy in a Mouse Model
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5371 - 5376.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Duda, R. K. Jain, and C. G. Willett
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Zhou, P. Guo, G. D. Kruh, P. Vicini, X. Wang, and J. M. Gallo
Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition
Clin. Cancer Res., July 15, 2007; 13(14): 4271 - 4279.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Q. Zhou, P. Guo, X. Wang, S. Nuthalapati, and J. M. Gallo
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 265 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson, and B. Lu
Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer
Cancer Res., December 1, 2006; 66(23): 11409 - 11415.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer
Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Emmenegger and R. S. Kerbel
A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs
Clin. Cancer Res., November 1, 2005; 11(21): 7589 - 7592.
[Full Text] [PDF]

Home page
 ScienceHome page
R. K. Jain
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Science, January 7, 2005; 307(5706): 58 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Gallo, P. Vicini, A. Orlansky, S. Li, F. Zhou, J. Ma, S. Pulfer, M. A. Bookman, and P. Guo
Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors
Clin. Cancer Res., December 1, 2004; 10(23): 8048 - 8058.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. K. Benjamin, F. H. Hochberg, E. Fox, P. M. Bungay, W. F. Elmquist, C. F. Stewart, J. M. Gallo, J. M. Collins, R. P. Pelletier, J. F. de Groot, et al.
Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium
Neuro-oncol, January 1, 2004; 6(1): 65 - 74.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Muramaki, H. Miyake, I. Hara, and S. Kamidono
Introduction of Midkine Gene into Human Bladder Cancer Cells Enhances Their Malignant Phenotype But Increases Their Sensitivity to Antiangiogenic Therapy
Clin. Cancer Res., November 1, 2003; 9(14): 5152 - 5160.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Ma, S. Li, K. Reed, P. Guo, and J. M. Gallo
Pharmacodynamic-Mediated Effects of the Angiogenesis Inhibitor SU5416 on the Tumor Disposition of Temozolomide in Subcutaneous and Intracerebral Glioma Xenograft Models
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 833 - 839.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.